Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Matt Hancock

- PMLiVE

AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants

New data from continued testing has shown that a third booster of Vaxzevria supports an increased antibody response against SARS-CoV-2 variants

- PMLiVE

Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine

Bourla was speaking in response to questioning during a healthcare conference as to whether a new jab would be needed to protect against Omicron

- PMLiVE

UK marks one-year anniversary of Oxford/AstraZeneca vaccine

The at-cost vaccine produced in the UK has been administered worldwide

- PMLiVE

J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study

The Sisonke study was done in South Africa while Omicron was the dominant variant

- PMLiVE

Pfizer/BioNTech receives expanded authorisation from the FDA for its COVID-19 booster

The booster dose of the companies’ COVID-19 vaccine is now authorised to include individuals aged 12 years and older

- PMLiVE

US prefers mRNA COVID-19 vaccines over J&J

Citing concerns over blood clots, Americans are now advised that should get the Pfizer-BioNTech or Moderna vaccines in preference to Johnson and Johnson vaccine

- PMLiVE

Sanofi/GSK vaccine boosts immune response

The vaccine boosted neutralising antibodies by 9 to 43-fold regardless of which vaccine was given as a primary course

- PMLiVE

South Africa releases first real-world evidence for Omicron

Briefing members of the UK parliament, the head of South Africa's Medical Association, Dr Angelique Coetzee, said the risk of severe COVID-19 was 29% lower with Omicron than Delta

- PMLiVE

UK supercharges booster programme over Omicron

The UK is to offer all vaccinated adults a COVID-19 booster to counter a ‘tidal wave of Omicron’ this winter, as evidence mounts of lower immunity from vaccines

- PMLiVE

FDA approves first pre-exposure prophylactic against COVID-19

AstraZeneca’s (AZ) Evushield offers long-acting protection against COVID-19 in people who are either unable to receive or mount an insufficient response to a vaccine

- PMLiVE

Omicron rise prompts tougher measures in England

The Omicron variant is spreading so rapidly in the UK that government experts predict 1,000-2,000 hospitalisations per day, prompting stricter control measures in England

- PMLiVE

Pfizer/BioNTech promote booster against Omicron

Preliminary laboratory studies suggest three doses of the Pfizer/BioNTech vaccine neutralises Omicron to the same extent as two doses neutralise the original, ‘wild-type’ SARS-CoV-2

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links